Modification of risk for cancer as a coincidental finding in DNA array investigation

Clinical Genetics

Volumn 83, Issue 3, 2013, Pages 284-287

  Rostasy, K ^a   Fauth, C ^a   Gautsch, K ^a   Laimer, I ^a   Krabichler, B ^a   Wimmer, K ^a   Fruhmesser A ^a   Kotzot, D ^a   Moshir, S ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

CHEK2; Deletion; Neurofibromatosis type 2; SNP array

Indexed keywords

CHECKPOINT KINASE 2; DNA;

ADULT; ARTICLE; CANCER RISK; CASE REPORT; CHROMOSOME ANALYSIS; DNA ARRAY; DNA DETERMINATION; FACE DYSMORPHIA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENETIC COUNSELING; GENETIC PREDISPOSITION; HUMAN; INTELLECTUAL IMPAIRMENT; MIXED HEARING LOSS; NEURILEMOMA; NEUROFIBROMATOSIS; NEUROFIBROMATOSIS TYPE 2; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; CHROMOSOME DELETION; CHROMOSOME DISORDERS; CHROMOSOMES, HUMAN, PAIR 22; FEMALE; HUMANS; INCIDENTAL FINDINGS; MAGNETIC RESONANCE IMAGING; NEUROFIBROMIN 2; NEUROMA, ACOUSTIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN-SERINE-THREONINE KINASES; RISK FACTORS;

EID: 84874017568     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2012.01881.x     Document Type: Article

References (19)

1. Evans DG. Neurofibromatosis type 2 (NF2). A clinical and molecular review. Orphanet J Rare Dis 2009: 4: 16.
2. Evans DG, Howard E, Giblin C et al. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A 2010: 152A (2): 327-332.
3. Bruder CE, Hirvelä C, Tapia-Paez I et al. High resolution deletion analysis of constitutional DNA from neurofibromatosis type 2 (NF2) patients using microarray-CGH. Hum Mol Genet 2001: 10 (3): 271-282.
4. Selvanathan SK, Shenton A, Ferner R et al. Further genotype-phenotype correlations in neurofibromatosis 2. Clin Genet 2010: 77 (2): 163-170.
5. Bruder CE, Ichimura K, Blennow E et al. Severe phenotype of neurofibromatosis type 2 in a patient with a 7.4-MB constitutional deletion on chromosome 22: possible localization of a neurofibromatosis type 2 modifier gene? Genes Chromosomes Cancer 1999: 25 (2): 184-190.
6. Blakeley JO, Evans DG, Adler J et al. Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. Am J Med Genet A 2011: 158A: 24-41.
7. Meijers-Heijboer H, van den Ouweland A, Klijn J et al. CHEK2-Breast Cancer Consortium. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002: 31 (1): 55-59.
8. Weischer M, Bojesen SE, Ellervik C, Tybjaerg-Hansen A, Nordestgaard BG. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26, 000 patient cases and 27, 000 controls. J Clin Oncol 2008: 26 (4): 542-548.
9. Oldenburg RA, Kroeze-Jansema K, Kraan J et al. The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families. Cancer Res 2003: 63 (23): 8153-8157.
10. Fletcher O, Johnson N, Dos Santos Silva I et al. Family history, genetic testing, and clinical risk prediction: pooled analysis of CHEK2 1100delC in 1, 828 bilateral breast cancers and 7, 030 controls. Cancer Epidemiol Biomarkers Prev 2009: 18 (1): 230-234.
11. Offit K, Garber JE. Time to check CHEK2 in families with breast cancer? J Clin Oncol 2008: 26 (4): 519-520.
12. Schwarzbraun T, Oberauf AC, Langmann A et al. Predictive diagnosis of the cancer prone Li-Fraumeni syndrome by accident: new challenges through whole genome array testing. J Med Genet 2009: 46: 341-344.
13. Schluth-Bolard C, Sanlaville D, Labalme A et al. 17p13.1 microdeletion involving the TP53 gene in a boy presenting with mental retardation but no tumor. Am J Med Genet 2010: 152A (5): 1278-1282.
14. Adam MP, Justice AN, Schelley S, Kwan A, Hudgins L, Martin CL. Clinical utility of array comparative genomic hybridization: uncovering tumor susceptibility in individuals with developmental delay. J Pediatr 2009: 154 (1): 143-146.
15. Krepischi-Santos AC, Rajan D, Temple IK et al. Constitutional haploinsufficiency of tumor suppressor genes in mentally retarded patients with microdeletions in 17p13.1. Cytogenet Genome Res 2009: 125 (1): 1-7.
16. Chabchoub E, Michils G, Vermeesch JR, De Cock P, Lagae L, Fryns JP. Duplication of the VHL and IRAK2 genes in a patient with mental retardation/multiple congenital anomalies, epilepsy and ectomorphic habitus. Genet Couns 2010: 21 (1): 35-40.
17. Adams SA, Coppinger J, Saitta SC et al. Impact of genotype-first diagnosis: the detection of microdeletion and microduplication syndromes with cancer predisposition by aCGH. Genet Med 2009: 11 (5): 314-322.
18. Pichert G, Mohammed SN, Ahn JW, Ogilvie CM, Izatt L. Unexpected findings in cancer predisposition genes detected by array comparative genomic hybridisation: what are the issues? J Med Genet 2011: 48: 530-534.
19. Bjørge T, Cnattingius S, Lie RT et al. Cancer risk in children with birth defects and in their families: a population-based cohort study of 5.2 million children from Norway and Sweden. Cancer Epidemiol Biomarkers Prev 2008: 17 (3): 500-506.